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Introduction 
Digoxin is a class-IV anti-arrhythmic 
which has indications for use in congestive 
heart failure and atrial dysrhythmias 
including atrial fibrillation, atrial flutter, and 
atrial tachycardia.1  It was prescribed first by 
Dr. William Withering for hydrops pectoris 
and described in An Account of the Foxglove 
and Some of Its Medical Uses in 1785.2 
Though digoxin has been used for over 200 
years, its properties and benefits continue to 
be investigated. Digoxin inhibits the 
sodium-potassium ATPase pump, thereby 
increasing intracellular sodium-calcium 
exchange in the cardiac myocyte.  The 
resultant increase in intracellular calcium 
causes increased contractility.  Digoxin also 
exerts an anti-adrenergic action in patients 
with heart failure by inhibiting sympathetic 
outflow.1,3 
While benefits of digoxin therapy were 
anecdotal for decades, in the early 1990s, 
PROVED, RADIANCE, and DIG trials 
showed prevention of clinical deterioration, 
decrease in hospitalizations, and improved 
exercise tolerance in digoxin treated patients 
despite the absence of an absolute survival 
advantage.4-6  Notwithstanding these proven 
benefits, digoxin utility has been restricted 
by a narrow therapeutic window.  Most 
cases of toxicity involve serum digoxin 
levels greater than two ng/mL, although 
digoxin’s interaction with many commonly 
used medications, including but not limited 
to  verapamil,  diltiazem,  erythromycin, and  
 
 
tetracycline may precipitate toxicity at 
therapeutic serum drug levels.  The 
mechanism of action may involve 
precipitating the AV-blocking effect (e.g., 
verapamil, diltiazem) or increasing the 
bioavailability of digoxin (e.g., macrolide 
antibiotics).  Advanced age, renal failure, 
ischemic heart disease, cardiomyopathy, and 
electrolyte disturbances including hypo-
kalemia, hypomagnesemia, and hyper-
calcemia also may predispose to toxicity.  
Toxicity may lead to neurologic, 
gastrointestinal, and/or cardiac symptoms, 
including headaches, dizziness, ataxia, 
yellow-green chromatopsia, nausea, 
vomiting, diarrhea, various cardiac 
dysrhythmias, and cardiac death.3,7 
Though gastrointestinal manifestations 
are often the first sign of digoxin toxicity, 
patients may present with cardiac 
arrhythmias which rapidly can progress to a 
fatal arrhythmia if unrecognized.  Premature 
ventricular beats or atrioventricular block 
are the earliest and most common abnormal 
rhythms found in up to 30-40% of verified 
cases of toxicity.7  Up to 80-90% of toxicity 
cases involve some type of cardiac 
arrhythmia.8 Treatment can prove 
challenging and may need to be multi-
faceted due to the many potential 
manifestations of digoxin toxicity.  
Supportive care, correction of electrolyte 
disturbances and use of digoxin-specific 
antibody Fab fragments to bind free digoxin  
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and aid in excretion are well documented. 
Fab fragments are pieces of the antibody 
that contain the antigen binding site.  
Treatment of dysrhythmias, if persistent 
despite administration of digoxin-specific 
antibody Fab fragments, is less 
standardized.8  Research has investigated the 
use of phenytoin to slow the development of 
digoxin-induced arrhythmias. The suspected 
mechanism of action involves a suppression 
of central sympathetic outflow, thereby 
decreasing ventricular automaticity.8  The 
utility of fosphenytoin, the pro-drug of 
phenytoin, for treatment of digoxin-induced 
arrhythmias has not been established. 
 
Case Report 
A 78-year-old Caucasian male was 
admitted with digoxin toxicity.  The patient 
was unable to provide a history.  His wife 
had observed one week of progressive 
weakness, lethargy, confusion, and anorexia.  
His past medical history was significant for 
ischemic cardiomyopathy with an ejection 
fraction of 10%, for which he took digoxin 
0.125 mg daily.  He also had mitral valve 
regurgitation, hyperlipidemia, hypertension, 
hypothyroidism, and peptic ulcer disease.  In 
addition to digoxin, his home medications 
included carvedilol, clopidogrel, furosemide, 
spironolactone, potassium chloride, 
gemfibrozil, hydrochlorothiazide/lisinopril, 
levothyroxine, and omeprazole.   
The patient was afebrile, with a pulse of 
59, blood pressure of 105/45 mmHg, 
respiratory rate of 8, and oxygen saturation 
of 99% on two liters per minute of oxygen 
via nasal canula.  The physical examination 
revealed a notably thin individual.  He was 
alert, however, oriented only to person and 
place.  His heart rate was bradycardic with a 
regular rhythm; no murmur, rub or gallop 
was present.  Serum chemistry revealed: 
BUN 193 mg/dL, creatinine 11.9 mg/dL, 
potassium 8 mEq/L, calcium 9.4 mg/dL, and 
magnesium  2.9  mg/dL.   The  digoxin level  
was elevated at 4.5 ng/mL.   
The initial electrocardiogram showed a 
left bundle branch block, unchanged from 
the month prior.  Chest radiograph showed 
cardiomegaly, without pulmonary vascular 
congestion.   
Intravenous fluids, albuterol solution via 
nebulizer, intravenous insulin with 50% 
dextrose and oral sodium polystyrene 
sulfonate (SPS) were administered to treat 
the hyperkalemia.  Since the patient’s 
hyperkalemia responded to medical 
treatment, emergent dialysis was not 
performed.  Confusion and hyperkalemia 
were presumed to be consequences of 
digoxin toxicity and digoxin Immune Fab 
was administered immediately using the 
following dosing formula:  serum digoxin 
concentration in ng/mL multiplied by weight 
in kg divided by 100. 
Despite digoxin-specific antibody Fab 
fragments, ventricular arrhythmias 
commenced with premature ventricular 
contractions (PVC), followed by ventricular 
bigeminy and brief runs of wide complex 
bradycardia (see Figure 1).  Shortly 
thereafter, the patient had a six beat run of 
ventricular tachycardia. 
Intravenous phenytoin was not readily 
available.  There was concern for use of 
lidocaine in the setting of progressive renal 
failure.  Fosphenytoin was given in a bolus 
at a dose of 20mg/kg IV.  Within one hour 
of the loading dose, a significant decrease in 
PVCs, bigeminy, and ectopy was noted (see 
Figure 2).  Digoxin Immune Fab treatment 
was repeated.  Fosphenytoin was continued 
every 12 hours for the remainder of the 
hospitalization.  Telemetry remained stable 
with infrequent PVCs over the duration of 
the hospital stay. 
Despite medical management of 
electrolytes and fluid balance, the patient’s 
renal function and uremia worsened and 
hemodialysis was initiated late on hospital 
day two.  Despite hemodialysis, the patient 
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Figure 1.   Telemetry demonstrating non-sustained ventricular tachycardia in addition to multiple 
premature ventricular beats. 
 
 
 
Figure 2. Telemetry demonstrating a substantial decrease in ventricular ectopy less than one hour 
after fosphenytoin loading.
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remained somnolent and confused. A 
decision was made by the family to change 
goals of care to comfort measures, and the 
patient expired on hospital day three. 
 
Discussion 
Historically, digoxin has been implicated 
as one of the most common causes of 
adverse drug reaction.9  Toxicity can be 
acute or chronic and symptoms of digoxin 
toxicity include gastrointestinal upset, 
neurologic findings, including visual 
disturbance and confusion, and cardiac 
dysrhythmia.10  In 10-15% of cases of 
documented toxicity, an ectopic cardiac 
rhythm is the first sign of intoxication.7  
Digoxin-induced arrhythmia occurs due 
to a depression of the sinoatrial node and its 
conduction which can lead to 
atrioventricular (AV) block and ventricular 
ectopy.  In turn, this can lead to increased 
automaticity, extra-systoles and tachy-
arrhythmia induced by the initiation of 
ectopic atrial pacemakers.  While PVCs, AV 
block, atrial tachycardia, and ventricular 
ectopy commonly are identified rhythms in 
digoxin toxicity, there are more specifically 
associated arrhythmias, including bi-
directional ventricular tachycardia usually 
resulting from an alteration of the 
intraventricular conduction pathway.  
Furthermore, ventricular ectopy may be 
more common in those patients with pre-
existing heart disease, as in our patient.7 
In this case, ventricular arrhythmias 
started with PVCs, followed by ventricular 
bigeminy and brief runs of wide complex 
tachycardia. The presence of a non-sustained 
ventricular tachycardia prompted initiation 
of antiarrhythmic treatment.  In digoxin-
induced arrhythmia, Class IA agents such as 
procainamide are contraindicated due to 
their impact of decreasing conduction, 
thereby propagating AV block.  In cases of 
severe bradyarrhythmia, atropine can be 
useful. The first line agents to treat 
ventricular ectopy are phenytoin and 
lidocaine; phenytoin has been shown to be 
more effective.7, 11 
Phenytoin’s efficacy in suppressing 
cardiac  ectopy  is  proposed  to be related to  
its effect on resting membrane potential, the 
action potential amplitude, and the upstroke 
velocity in phase 0 of the cardiac cycle.  In 
the presence of a low serum potassium, 
phenytoin can increase the action potential 
of both atrial and Purkinje fibers, enhancing 
conduction and increasing the phase 0 
upstroke velocity.  Less is known about the 
effect of phenytoin on a reentrant circuit in 
the presence of normal serum potassium.  
(In our patient, serum potassium had been 
normalized by the time of fosphenytoin 
administration).   
Phenytoin may improve conduction of 
premature impulses and in the setting of 
digoxin toxicity depress spontaneous 
diastolic depolarization.  Though phenytoin 
has been effective for ventricular ectopy 
associated with digoxin overdose, little 
effect has been seen in treating atrial 
arrhythmia or ventricular arrhythmia in the 
setting of chronic cardiac disease.11  The 
reported dose of phenytoin is 250 mg IV 
over 10 minutes which can be repeated in 
boluses of 100 mg every five minutes up to 
one gram.7  Intravenous phenytoin must be 
used with caution in patients with pre-
existing hypotension and may cause 
hypotension if it is administered at rates 
exceeding 50 mg/min.  Fosphenytoin for the 
treatment of digoxin-induced cardiac 
arrhythmia has not been reported.7 
Fosphenytoin is a pro-drug of phenytoin, 
hydrolyzed into phenytoin in-vivo.  Benefits 
of intravenous fosphenytoin treatment as 
compared to intravenous phenytoin are 
related to an increased water-solubility, thus 
decreasing injection site reactions and 
allowing faster administration. The intra-
venous preparation of phenytoin contains 
approximately 40% propylene glycol in 
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addition to ethanol, leading to an alkaline 
pH of 12.  Fosphenytoin, with a pH of 8.8, is 
compatible with most intravenous fluids.12  
The propylene glycol in intravenous 
phenytoin has been shown in some cases to 
lead to increased hypotension and cardiac 
arrhythmia in studies on acute seizure 
treatment.12,13  Fosphenytoin is less likely to 
cause hemodynamic instability.  The lack of 
immediate availability of intravenous 
phenytoin and the ability to infuse 
fosphenytoin more rapidly prompted 
treatment with this agent.  This resulted in a 
substantial reduction in the patient’s 
ventricular ectopy, presumably by the same 
antiarrhythmic mechanism as phenytoin.  He 
was treated with fosphenytoin through the 
duration of his hospitalization with no 
known direct complications of therapy. 
 
Conclusions 
This case was a 78-year-old male with 
digoxin toxicity who developed ventricular 
arrhythmias.  The presence of the elevation 
of free digoxin with the risk of further 
dysrhythmia precludes the use of many 
traditional antiarrhythmics.  This patient’s 
deteriorating renal function cautioned use of 
lidocaine. At this institution, limited 
availability of intravenous phenytoin 
prompted use of intravenous fosphenytoin 
which decreased the ventricular ectopy.  
Administration of intravenous fosphenytoin, 
shown to result in fewer incidences of 
infusion site phlebitis and rate-dependent 
hypotension as compared to intravenous 
phenytoin, may be an alternative therapy in 
an attempt to suppress ventricular ectopy 
associated with digoxin toxicity. 
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